{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:50:58Z","timestamp":1791489058336,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy and safety reports of ixekizumab for moderate\u2010to\u2010severe plaque psoriasis may vary between clinical trials and real\u2010world studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To analyze the real\u2010world data of ixekizumab therapy to evaluate its efficacy and safety and highlight the factors influencing the treatment response in the real\u2010world scenario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients\/Methods<\/jats:title>\n                    <jats:p>Data of 82 adult patients with moderate\u2010to\u2010severe chronic plaque psoriasis are included in this study. Psoriasis area severity index (PASI) 75\/90\/100 responses at 4, 16, 24, and 48\u2009weeks were analyzed retrospectively from patient charts by examining demographic and clinical characteristics of the patients, especially their previous biologic experience, obesity, and involvement of hard\u2010to\u2010treat areas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PASI75, PASI90, and PASI100 responses were achieved in 92.4%, 86.1%, and 26.6% patients at week 16 and maintained till week 48 in 92.3%, 86.5%, and 17.3% patients. PASI90 responses in obese patients were significantly lower than non\u2010obese patients at week 4 (33.3% vs. 69.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.042), but this difference was minimized by week 16 (82.4% vs. 90%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.405). PASI90 responses in biologic\u2010naive patients were significantly higher than biologic\u2010experienced patients at week 16 (\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u00a00.015). Involvement of hard\u2010to\u2010treat areas was negatively associated with PASI90 responses at week 16 (OR: 1591805.842; 95% CI: 1.223\u20132071404486740.201;\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u00a00.047).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ixekizumab provides an effective and safe biologic treatment option to patients with moderate\u2010to\u2010severe plaque psoriasis. Obesity, though it affects the early treatment response (till week 4), does not upset the overall treatment response beyond week 16. Previous biologic exposure and involvement of hard\u2010to\u2010treat areas are important prognostic factors for achieving high PASI responses in psoriatic patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jocd.15217","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T03:59:17Z","timestamp":1657252757000},"page":"6215-6224","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ixekizumab treatment in patients with moderate\u2010to\u2010severe plaque psoriasis in a real\u2010world clinical setting"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5051-5481","authenticated-orcid":false,"given":"Neslihan","family":"Demirel \u00d6\u011f\u00fct","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology U\u015fak Training and Research Hospital  U\u015fak Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0633-1770","authenticated-orcid":false,"given":"Sema","family":"Ko\u00e7 Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology U\u015fak Training and Research Hospital  U\u015fak Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Erba\u011fc\u0131","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology U\u015fak Training and Research Hospital  U\u015fak Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Asl\u0131","family":"Hapa","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology \u0130zmir Democracy University  \u0130zmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.09.004"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17403"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12817"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.194"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16181"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14237"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15670"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17849"},{"key":"e_1_2_11_14_1","unstructured":"Republic of Turkey Ministry of Health.Turkey Republic Vaccine Application Strategies.https:\/\/covid19asi.saglik.gov.tr\/TR\u201077706\/covid\u201019\u2010asisi\u2010ulusal\u2010uygulama\u2010stratejisi.html. Accessed February 21 2022."},{"issue":"1","key":"e_1_2_11_15_1","first-page":"1","article-title":"Turkey psoriasis treatment Guide\u20102016","volume":"50","author":"Akyol M","year":"2016","journal-title":"Turkderm\u2010Turk Arch Dermatol Venereol"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15288"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12886"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.02.006"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00490-2"},{"key":"e_1_2_11_20_1","first-page":"1","article-title":"Moderate\u2010to\u2010severe plaque psoriasis patients treated with ixekizumab: early real\u2010world outcomes and adverse events [published online ahead of print, 2020 Apr 22]","volume":"33","author":"Gulliver W","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14066"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1952154"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16050"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13990"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01080-z"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16083"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18361"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00559-z"},{"issue":"2","key":"e_1_2_11_29_1","first-page":"200","article-title":"Safety and tolerability of Ixekizumab: integrated analysis of injection\u2010site reactions from 11 clinical trials","volume":"17","author":"Shear NH","year":"2018","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.15217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:05:29Z","timestamp":1791486329000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/jocd.15217"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15217","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"2022-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}